The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudyReportar como inadecuado




The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Rationale and objective

Endothelial progenitor cells EPCs play a role in vascular repair, while circulating endothelial cells CECs are biomarkers of vascular damage and regeneration. Statins may promote EPC-CEC mobilization in the peripheral blood. We evaluated whether pre-procedural exposure to different lipid-lowering drugs statins±ezetimibe can acutely increase levels-activity of EPCs-CECs in patients with stable coronary artery disease CAD.

Methods

In a planned sub-analysis of the Rosuvastatin For REduction Of Myocardial DamagE During Coronary AngioplastY REMEDY trial, 38 patients with stable CAD on chronic low-dose statin therapy were randomized, in a double-blind, placebo-controlled design, into 4 groups before PCI: i. placebo n = 11; ii. atorvastatin 80 mg+40 mg, n = 9; iii. rosuvastatin 40 mg twice, n = 9; and iv. rosuvastatin 5 mg and ezetimibe 10 mg twice, n = 9. At baseline and 24 h after treatment–before PCI–, patients underwent blinded analyses of EPCs colony forming units-endothelial cells CFU-ECs, endothelial colony-forming cells ECFCs and tubulization activity and CECs in peripheral blood.

Results

We found no significant treatment effects on parameters investigated such as number of CECs Median IQR: i. 00, ii. 4.527, iii. 1.92.3, iv. 1.92.3, CFU-ECs Median IQR: i. 2711, ii. 1931, iii. 4736, iv. 3098, and ECFCs Median IQR: i. 8684, ii. 784, iii. 8-42.5, iv. 52, as well as tubulization activity total tubuli well, Median IQR: i. 197, ii. 54, iii. 2513, iv. 1524.

Conclusions

In this study, we found no evidence of acute changes in levels or activity of EPCs and CECs after high-dose lipid-lowering therapy in stable CAD patients.



Autor: Rosalinda Madonna, Francesca Vera Renna, Paola Lanuti, Matteo Perfetti, Marco Marchisio, Carlo Briguori, Gerolama Condorelli, Lam

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados